Immunobiology (ImmBio), a UK-based biopharmaceutical company, has bagged £0.2m in funding from the UK government-backed Biomedical Catalyst (BBC) for the pre-clinical development of pneumococcal vaccine PnuBioVax. The pharma company ...
The research collaboration will leverage Mucosis' Mimopath platform technology in Crucell's program for developing undisclosed novel vaccines to combat infectious diseases. Mucosis CEO Thomas Johnston said Mimopath platform combined ...
Tags: License Option Agreement, biotechnology, novel vaccines